Quarterly report pursuant to Section 13 or 15(d)

Basis of Presentation and Significant Accounting Policies (Details Narrative)

v3.7.0.1
Basis of Presentation and Significant Accounting Policies (Details Narrative)
3 Months Ended 6 Months Ended 12 Months Ended
Jun. 30, 2017
USD ($)
Jun. 30, 2016
USD ($)
Jun. 30, 2017
USD ($)
Breathlyzers
Jun. 30, 2016
USD ($)
Dec. 31, 2016
USD ($)
Allowances for doubtful accounts for trade receivables $ 192,435   $ 192,435   $ 1,010,196
Bad debt expenses 5,380 $ 146,196 47,741 $ 146,196  
Deferred revenue     24,294   41,120
Revenue recognition rebates expense 67,855 115,685 170,678 215,653  
Shipping, handling and transportation costs 15,049 14,387 33,469 30,432  
Cost of net revenue 31,393 $ 47,018 $ 47,570 $ 68,732  
Product Revenue [Member]          
Concentration risk percentage     68.00%    
Trade Receivable [Member]          
Concentration risk percentage     62.00%    
Concentration risk, number of customer | Breathlyzers     3    
Fulton Bank of New Jersey [Member]          
Cash 182,913   $ 182,913   67,865
Bank of America [Member]          
Cash 10,222   10,222   795
PayPal [Member]          
Cash 4,040   $ 4,040   $ 4,040
Minimum [Member]          
Normal credit terms extended to customers     30 days    
Maximum [Member]          
Normal credit terms extended to customers     90 days    
Cash, FDIC insured amount $ 250,000   $ 250,000    
Maximum [Member] | Patents [Member]          
Finite-lived intangible asset, useful life     17 years